The changing landscape of advanced and castration resistant prostate cancer: Latest science and revised definitions

Canadian Journal of Urology

Volumn 21, Issue , 2014, Pages 7-13

  Tilki, Derya ^a,b   Evans, Christopher P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Androgen receptor; Castration resistant; Hormone refractory; Prostate cancer; Review

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR;

DISEASE COURSE; HUMAN; MALE; NOMENCLATURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGENS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TERMINOLOGY AS TOPIC;

EID: 84927565818     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
2. Studer UE, Hauri D, Hanselmann S et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004;22(20):4109-4118.
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85.
4. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11(3):459-476.
5. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005.
6. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-148.
7. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-1197.
8. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000;55(3): 323-327.
9. Bastian PJ, Boorjian SA, Bossi A et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61(6):1096-1106.
10. Chang SS, Benson MC, Campbell SC et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005;103(1):11-21.
11. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32(49):5501-5511.
12. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 2011;1(6):466-468.
13. Beltran H, Tagawa ST, Park K et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012;30(36):e386-e389.
14. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43209-43223.
15. Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
16. Lamont KR, Tindall DJ. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011;25(6):897-907.
17. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010;5(10):e13500.
18. Fowler JE, Jr., Whitmore WF, Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982;49(7):1373-1377.
19. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995;46(2):142-148.
20. Chen Y, Scher HI. Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat Rev Clin Oncol 2012;9(2): 70-72.
21. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11(14):5223-5232.
22. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021-1024.
23. Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178(4 Pt 1): 1290-1295.
24. Saad F, Hotte SJ. Guidelines for the management of castrateresistant prostate cancer. Can Urol Assoc J 2010;4(6):380-384.
25. Cookson MS, Roth BJ, Dahm P et al. Castration-Resistant Prostate Cancer: AUA Guideline. J Urol 2013;190(2):429-438.
26. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26(7):1148-1159.
27. Centenera MM, Harris JM, Tilley WD, Butler LM. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol 2008;22(11): 2373-2382.
28. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13): 3001-3015.
29. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2013 Epub ahead of print.
30. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14(2):121-141.
31. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
32. Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012;24(3):251-257.
33. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61(7):2892-2898.
34. Wright JL, Kwon EM, Ostrander EA et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2011; 20(4): 619-627.
35. Yang M, Xie W, Mostaghel E et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011;29(18):2565-2573.
36. Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57(2):314-319.
37. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401-406.
38. Labrie F, Belanger A, Dupont A et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16(6):475-492.
39. Adachi M, Takayanagi R, Tomura A et al. Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 2000; 343(12):856-862.
40. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61(11):4315-4319.
41. Buchanan G, Greenberg NM, Scher HI et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7(5):1273-1281.
42. Gottlieb B, Lehvaslaiho H, Beitel LK et al. The Androgen Receptor Gene Mutations Database. Nucleic Acids Res 1998;26(1): 234-238.
43. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60(4):944-949.
44. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-1398.
45. Cai C, He HH, Chen S et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011;20(4):457-471.
46. Chang YM, Bai L, Liu S et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27(49):6365-6375.
47. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5(3):280-285.
48. Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54(20):5474-5478.
49. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68(13):5469-5477.
50. Graff JR, Konicek BW, McNulty AM et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275(32):24500-24505.
51. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN Jr. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2007;10(4):331-339.
52. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998;393 (6680):83-85.
53. Sharma A, Yeow WS, Ertel A et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120(12):4478-4492.
54. Sun S, Sprenger CC, Vessella RL et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120(8): 2715-2730.
55. Wang Q, Li W, Zhang Y et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138(2):245-256.
56. Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107(39):16759-16765.
57. Yeh S, Lin HK, Kang HY et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96(10): 5458-5463.
58. Colombel M, Symmans F, Gil S et al. Detection of the apoptosissuppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143(2):390-400.
59. Gleave M, Tolcher A, Miyake H et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5(10):2891-2898.
60. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL. Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996; 65(1):85-89.
61. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940-6944.
62. Brand LJ, Dehm SM. Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Curr Drug Targets 2013;14(4):441-449.
63. MacVicar GR, Hussain MH. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 2013;25(3):252-260.
64. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19(1):43-49.
65. Sharifi N. Minireview: Androgen metabolism in castrationresistant prostate cancer. Mol Endocrinol 2013;27(5):708-14.
66. Hornberg E, Ylitalo EB, Crnalic S et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011;6(4):e19059.
67. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 2011;71(4):1208-1213.
68. Andersen RJ, Mawji NR, Wang J et al. Regression of castraterecurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17(6):535-546.
69. Yang L, Lin C, Jin C et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013:500(7464):598-602.
70. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev 1998;17(4):391-399.
71. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26(2):263-273.
72. Locke JA, Guns ES, Lehman ML et al. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2010;70(3):239-351.
73. Lubik AA, Gunter JH, Hendy SC et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 2011;71(17):5754-5764.
74. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68(11):4447-4454.
75. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15): 6407-6415.